MediWound (MDWD) Expected to Announce Quarterly Earnings on Thursday

MediWound (NASDAQ:MDWD) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $2.0870 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

MediWound Stock Performance

NASDAQ:MDWD opened at $17.41 on Tuesday. The firm has a 50-day moving average price of $17.82 and a two-hundred day moving average price of $17.88. MediWound has a 52 week low of $14.14 and a 52 week high of $22.50. The firm has a market cap of $223.02 million, a price-to-earnings ratio of -9.16 and a beta of 0.13.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Kotler Kevin bought a new stake in MediWound during the 4th quarter valued at approximately $6,225,000. Millennium Management LLC increased its position in shares of MediWound by 355.6% during the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after purchasing an additional 136,884 shares during the last quarter. Sphera Funds Management LTD. raised its stake in shares of MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after acquiring an additional 45,077 shares during the period. Summit Financial LLC lifted its stake in MediWound by 200.1% in the fourth quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company’s stock worth $886,000 after purchasing an additional 32,006 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of MediWound by 22.8% during the 4th quarter. Geode Capital Management LLC now owns 120,101 shares of the biopharmaceutical company’s stock worth $2,217,000 after acquiring an additional 22,268 shares during the last quarter. Institutional investors own 46.83% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on MDWD shares. Wall Street Zen raised MediWound from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $31.67.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.